Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label study of efanesoctocog alfa in previously treated patients with severe hemophilia A
jRCT2031210133Phase 3Active, not recruiting
- Sponsor
- Sanofi
- Start
- Jun 2021
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
01
Overview
Phase 3, open-label trial of efanesoctocog alfa in hemophilia A (3 arms), sponsored by Sanofi. Primary endpoint: Number of participants with inhibitor development. Started Jun 2021; status: active, not recruiting.
02
Drugs
efanesoctocog alfa
03
Conditions
hemophilia A
Beyond the preview
Go deeper on jRCT2031210133.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210133.